Benefit of Carbon Ion Radiotherapy in the Treatment of Radio-resistant Tumors

Journal Article · Tue Aug 26 04:00:00 EDT 2003 · AIP Conference Proceedings

DOI:https://doi.org/10.1063/1.1619910· OSTI ID:20632548

Kamada, Tadashi; Tsujii, Hirohiko; Tsuji, Hiroshi; Yanagi, Tsuyoshi; Imai, Reiko; Mizoe, Jun-etsu; Miyamoto, Tadaaki; Kato, Hirotoshi; Yamada, Shigeru; Kato, Shingo; Yoshikawa, Kyousan; Kandatsu, Susumu ^[1]

---

1. Research Center Hospital for Charged Particle Therapy, National Institute of Radiological Sciences Chiba 263-8555 (Japan)

The Heavy Ion Medical Accelerator in Chiba (HIMAC) is the world's first heavy ion accelerator complex dedicated to medical use in a hospital environment. Heavy ions have superior depth-dose distribution and greater cell-killing ability. In June 1994, clinical research for the treatment of cancer was begun using carbon ions generated by HIMAC. Until August 2002, a total of 1,297 patients were enrolled in clinical trials. Most of the patients had locally advanced and/or medically inoperable tumors. Tumors radio-resistant and/or located near critical organs were also included. The clinical trials revealed that carbon ion radiotherapy provided definite local control and offered a survival advantage without unacceptable morbidity in a variety of tumors that were hard to cure by other modalities.

• OSTI ID: 20632548
• Journal Information: AIP Conference Proceedings, Journal Name: AIP Conference Proceedings Journal Issue: 1 Vol. 680; ISSN 0094-243X; ISSN APCPCS
• Country of Publication: United States
• Language: English

Related Subjects

43 PARTICLE ACCELERATORS
62 RADIOLOGY AND NUCLEAR MEDICINE
CARBON IONS
CELL KILLING
CLINICAL TRIALS
CONTROL
CRITICAL ORGANS
DEPTH DOSE DISTRIBUTIONS
DISEASE INCIDENCE
HEAVY ION ACCELERATORS
HEAVY IONS
ION BEAMS
NEOPLASMS
PATIENTS
RADIOTHERAPY